In the case of the AFP, the hepatocellular carcinoma (HCC) showed a sensitivity of 77.8%, a specificity of 98.6%, and 3.25% of positive predictive value. And our study showed that the relative risk of a malignant tumor rose significantly as the cut-off value of CEA and CA 19-9 increased (p < 0.05). Moreover, combined tumor marker elevation increased the relative risk of malignancy. Among the patients with elevated CEA and CA 19-9 levels, the relative risk was 10.217. It is higher than the elevated CEA alone (relative risk 3.694) or the elevated CA 19-9 alone (relative risk 5.154). Similar results were Pifithrin �� represented in sub-groups of lung, gastric and bile duct cancer,

but not shown in pancreatic cancer. Conclusion: Usefulness of tumor markers for cancer detection is limited because of low sensitivity and low positive predictive value. However, higher cut-off values and combined tumor marker elevation have increased the relative risk of malignancy. We need to set up fine-grained methodology for analysis of tumor markers. And application

to individuals will increase the usefulness of tumor markers for purposes of conducting at health screenings. Key Word(s): 1. tumor markers; 2. early detection of cancer; 3. carcinoembryonic antigen; 4. carbohydrate antigen 199; 5. alpha-fetoprotein Presenting Author: SOH EE LEE Additional Authors: REUBEN WONG, SOH EE LEE, WAI-KIT CHEONG, YOCK YOUNG DAN, LI LIN LIM, FENG ZHU, CHRIS LEE, WAI LEONG QUAN, STEPHEN TSAO, CHARLES VU, WEI-LYN YANG, RICHARD SIM, KHAY GUAN

YEOH Corresponding Author: SOH EE LEE Affiliations: National University Health System, National University of Singapore, National University Regorafenib solubility dmso Health System, National University Health System, National University Health System, National University of Singapore, National University of Singapore, Tan Tock Seng Hospital, Tan Tock Seng Hospital, Tan Tock Seng Hospital, Tan Tock Seng Hospital, National University of Singapore Objective: Background: The Asia Pacific Colorectal Screening (APCS) score is a clinical risk score predictive of risk for colorectal advanced 上海皓元医药股份有限公司 neoplasia for Asia. Aim: To assess the utility of the APCS score in prioritizing screening colonoscopies for asymptomatic subjects. Methods: Methods: Colonoscopy data incorporating demographic risk factors and endoscopy findings were prospectively collected via an automated endoscopy system. Advanced neoplasia was defined as adenomas >10 mm, villous polyps, high grade dysplasia or adenocarcinoma. To calculate an APCS score, points were assigned to each risk factor for advanced neoplasia: age 50–69 years (2), ≥70 years (3), male gender (1), family history of colorectal cancer (2), and smoking (1). According to their APCS score, subjects were grouped into three risk tiers: score 0–1 ‘average risk’, AR; score 2–3 ‘moderate risk’, MR; and score 4–7 ‘high risk’, HR. Results: Results: Applying the APCS score to 2054 asymptomatic subjects, 238 (11.6%), 1333 (64.9%) and 483 (23.